Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Mallinckrodt Public Limited Company (NYSE: MNK) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Mallinckrodt Public Limited Company (NYSE: MNK) concerning whether a series of statements by Mallinckrodt Public Limited Company regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 16, 2016, Citron Research issued a report titled "Mallinckrodt CEO FRAUD exposed by the new Medicare Drug Dashboard", stating in the report that Mallinckrodt CEO, Mark C. Trudeau, has committed Fraud by lying to the shareholders about the Company's dependence on the Medicare system.  According to Citron, Mallinckrodt drug Acthar, is currently the most expensive drug reimbursed by Medicare.

On this news, NYSE: MNK fell $8.15 per share or roughly 12% to close at $59.65 per share on November 16, 2016.

Based in Chesterfield, the United Kingdom, Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents worldwide.

If you purchased shares of Mallinckrodt Public Limited Company (NYSE: MNK) on or before November 16, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185